Visitor restrictions and mask requirements are still in place at all Scripps facilities. If you suspect you have COVID, please visit MyScripps first and answer the COVID-19 Symptom Checker questions. 

Your browser is out-of-date!

Internet Explorer 11 has been retired by Microsoft as of June 15, 2022. To get the best experience on this website, we recommend using a modern browser, such as Safari, Chrome or Edge.


Investigational device for tricuspid valve replacement

Trial ID:
Curtiss Stinis, MD
This study will evaluate the safety and effectiveness of the investigational EVOQUE System combined with optimal medical therapy (OMT) compared to OMT alone for the treatment of patients with severe or greater tricuspid regurgitation.

Inclusion Criteria

Patients must:
  • Be Age 18 years or older.
  • Have severe tricuspid regurgitation.
  • Be appropriate for transcatheter tricuspid valve replacement.

Exclusion Criteria

Patients must not:
  • Be unable to walk at least 100 meters in a 6-minute walk test.
  • Have a prior heart transplant.
  • Have a prior annuloplasty ring implant.
  • Be using continuous home oxygen for primary severe COPD.
  • Have a known bleeding or clotting disorders

Additional Info

  • The EVOQUE system is a tricuspid valve replacement system that uses a transcatheter procedure with no open-heart surgery.
  • Eligible patients will be randomized to receive treatment with the EVOQUE System or Optimal Medical Therapy (standard of care), and will have follow-up visits at 30 days, 6 months, 12 months and then annually for up to 5 years.
  • Search for NCT04482062 at for more information.

Contact Info:

  • CRS Leadership